- Home
- LBTYB vs TVTX Comparison
LBTYB vs TVTX Comparison
Compare LBTYB & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYB | TVTX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.3B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LBTYB | TVTX |
|---|---|---|
| Price | $13.15 | $65.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $40.62 |
| AVG Volume (30 Days) | 2.7K | ★ 1.2M |
| Earning Date | 02-18-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $11,541,500,000.00 | N/A |
| Revenue This Year | $15.41 | $44.76 |
| Revenue Next Year | $3.03 | $35.51 |
| P/E Ratio | $13.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.20 | $22.06 |
| 52 Week High | $29.01 | $68.03 |
Technical Indicators
Market Signals| Indicator | LBTYB | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 60.45 |
| Support Level | $12.18 | $53.76 |
| Resistance Level | $14.14 | $66.24 |
| Average True Range (ATR) | 0.36 | 1.98 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 75.59 | 71.85 |
Price Performance
Historical ComparisonAbout LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.